Old farts [General Sta­tis­tics]

posted by vezz – Erba (CO), Italy, 2009-12-10 19:10 (6031 d 08:52 ago) – Posting: # 4463
Views: 11,426

Dear D. Labes and Helmut,

thank you for sharing your experienced viewpoint. As you, I have never used models including simple carryover effect and I'm not pursuing this approach.

I was thinking again about the interpretation of sequence effect in designs with more than two treatments and an equal number of periods. Probably, if we assume that carryover of higher order are extremely unlikely, its interpretation is analogous to that given in 2x2 design.

As regards the inclusion of sequence effect in BE studies, I think that the book by Jones and Kenward [*] shows an interesting feature. This variable is not included in any model until the last chapter (7. Bioequivalence trials), where it is stated: "Following common practice we will also fit a sequence or group effect" (section 7.1). What I am really interested in is the rationale behind this "common practice".

Thank you again for your help.

[*] B. Jones, M.G. Kenward, "Design and Analysis of Cross-Over Trials", Second edition, Chapman & Hall/CRC 2003.

Kind regards,

Stefano

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
146 visitors (0 registered, 146 guests [including 19 identified bots]).
Forum time: 05:03 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5